PL322409A1 - Reversible protease inhibitors - Google Patents

Reversible protease inhibitors

Info

Publication number
PL322409A1
PL322409A1 PL96322409A PL32240996A PL322409A1 PL 322409 A1 PL322409 A1 PL 322409A1 PL 96322409 A PL96322409 A PL 96322409A PL 32240996 A PL32240996 A PL 32240996A PL 322409 A1 PL322409 A1 PL 322409A1
Authority
PL
Poland
Prior art keywords
protease inhibitors
reversible protease
reversible
inhibitors
protease
Prior art date
Application number
PL96322409A
Inventor
James T Palmer
David Rasnick
Jeffrey L Klaus
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of PL322409A1 publication Critical patent/PL322409A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyridine Compounds (AREA)
PL96322409A 1995-03-24 1996-03-21 Reversible protease inhibitors PL322409A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40999695A 1995-03-24 1995-03-24
PCT/US1996/003844 WO1996030353A1 (en) 1995-03-24 1996-03-21 Reversible protease inhibitors

Publications (1)

Publication Number Publication Date
PL322409A1 true PL322409A1 (en) 1998-01-19

Family

ID=23622800

Family Applications (1)

Application Number Title Priority Date Filing Date
PL96322409A PL322409A1 (en) 1995-03-24 1996-03-21 Reversible protease inhibitors

Country Status (15)

Country Link
EP (1) EP0817778A1 (en)
JP (1) JPH11503417A (en)
KR (1) KR19980703261A (en)
CN (1) CN1071751C (en)
AU (1) AU713492B2 (en)
CA (1) CA2216151A1 (en)
CZ (1) CZ298197A3 (en)
IL (1) IL117638A0 (en)
MY (1) MY113489A (en)
NO (1) NO311573B1 (en)
NZ (1) NZ305626A (en)
PL (1) PL322409A1 (en)
TW (1) TW470750B (en)
WO (1) WO1996030353A1 (en)
ZA (1) ZA962336B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723447B2 (en) 1996-04-22 2000-08-24 Brigham And Women's Hospital Suppression of immune response via inhibition of cathepsin S
EP0934293A1 (en) * 1996-07-30 1999-08-11 Arris Pharmaceutical Corporation Novel compounds and compositions for treating diseases associated with tryptase activity
DE19817461A1 (en) * 1998-04-20 1999-10-21 Basf Ag New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
PL345817A1 (en) * 1998-08-04 2002-01-14 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
WO2000018738A1 (en) * 1998-09-25 2000-04-06 Astrazeneca Ab Benzamide derivatives and their use as cytokine inhibitors
JP2002538151A (en) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Compounds useful as reversible inhibitors of cathepsin
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
HUP0302380A2 (en) * 1999-09-13 2004-03-01 Boehringer Ingelheim Pharmaceuticals, Inc. Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases, process for their preparation and pharmaceutical compositions containing them
AU784746B2 (en) 1999-11-18 2006-06-08 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6635633B2 (en) 2000-08-14 2003-10-21 Ortho-Pharmaceutical, Inc. Substituted pyrazoles
US7589202B2 (en) 2000-08-14 2009-09-15 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
RU2317988C2 (en) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Substituted pyrazoles, pharmaceutical composition based on thereof, using pharmaceutical composition and method for inhibition of cathepsin s activity
HK1053129A1 (en) 2000-09-06 2003-10-10 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies
US20020107266A1 (en) * 2000-12-12 2002-08-08 Marguerita Lim-Wilby Compounds, compositions and methods for treatment of parasitic infections
MXPA03005601A (en) 2000-12-22 2004-12-02 Axys Pharm Inc Novel compounds and compositions as cathepsin inhibitors.
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
CA2441378A1 (en) 2001-03-22 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
WO2002077267A2 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
WO2002092841A2 (en) 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
CN1324008C (en) 2001-09-14 2007-07-04 安万特药物公司 Novel compounds and compositions as cathepsin inhibitors
WO2003024923A1 (en) * 2001-09-14 2003-03-27 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
CN1324018C (en) 2001-11-14 2007-07-04 安万特药物公司 Oligopeptides and compositions containing them as cathepsin S inhibitors
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
AU2009250295B2 (en) 2008-05-21 2014-05-01 Genesis Technologies Limited Selective caspase inhibitors and uses thereof
US9045524B2 (en) 2009-05-21 2015-06-02 Novagenesis Foundation Selective caspase inhibitors and uses thereof
WO2011069149A2 (en) 2009-12-04 2011-06-09 Dcb-Usa Llc Cathepsin s inhibitors
CA2833082C (en) 2011-04-15 2019-12-31 New World Laboratories, Inc. Selective cysteine protease inhibitors and uses thereof
KR101309578B1 (en) * 2011-05-06 2013-09-17 연세대학교 산학협력단 Dityrosine compounds having selectivity for cysteine proteases and method for monitoring cysteine proteases using the same
KR101385855B1 (en) * 2012-10-16 2014-04-22 이동익 Diaromatic amino acid-based substrate for detecting cathepsins
CN111601813A (en) * 2018-01-19 2020-08-28 株式会社大阪曹达 Organic silicon compound and rubber composition using same
EP3553521A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Gingivitis diagnostic methods, uses and kits

Also Published As

Publication number Publication date
CA2216151A1 (en) 1996-10-03
EP0817778A1 (en) 1998-01-14
ZA962336B (en) 1996-07-31
NZ305626A (en) 2000-01-28
JPH11503417A (en) 1999-03-26
NO311573B1 (en) 2001-12-10
KR19980703261A (en) 1998-10-15
TW470750B (en) 2002-01-01
CN1071751C (en) 2001-09-26
NO974403D0 (en) 1997-09-23
NO974403L (en) 1997-11-17
MY113489A (en) 2002-03-30
CN1184472A (en) 1998-06-10
AU5367496A (en) 1996-10-16
IL117638A0 (en) 1996-07-23
WO1996030353A1 (en) 1996-10-03
AU713492B2 (en) 1999-12-02
CZ298197A3 (en) 1998-03-18

Similar Documents

Publication Publication Date Title
PL322409A1 (en) Reversible protease inhibitors
PL326508A1 (en) Protease inhibitors
ZA964751B (en) Reversible cysteine protease inhibitors
PL336625A1 (en) Protease inhibitors
EP0744948A4 (en) Protease inhibitors
HU9601508D0 (en) Dp-iv-serine protease inhibitors
PL336589A1 (en) Serinic protease inhibitors
HUP9903863A3 (en) Metalloproteinase inhibitors
PL328307A1 (en) Serinic protease inhibitors
PL337755A1 (en) Protease inhibitors
HUP0002247A3 (en) Protease inhibitors
ZA983522B (en) Protease inhibitors
PL328875A1 (en) Serinic protease inhibitors
ZA988479B (en) Protease inhibitors
PL328223A1 (en) Aspartil protease inhibitors
ZA988064B (en) Protease inhibitors
ZA961225B (en) Serine protease inhibitors
EP0975612A4 (en) Protease inhibitors
GB9520761D0 (en) Protease inhibitors
GB9500946D0 (en) Protease inhibitors
GB2318353B (en) Metalloproteinase inhibitors
GB9420277D0 (en) Protease inhibitors
HK1022303A (en) Protease inhibitors
GB9503754D0 (en) Metalloproteinase inhibitors
GB9506107D0 (en) Metalloproteinase inhibitors